Loading
A phase 1/2 trial of Vimseltinib in tenosynovial giant cell tumour, run by Deciphera Pharmaceuticals, LLC, active and no longer recruiting.
Study of Vimseltinib (DCC-3014) in Patients With Advanced Tumors and Tenosynovial Giant Cell Tumor is a phase 1/2 interventional study registered as NCT03069469 by Deciphera Pharmaceuticals, LLC, with 120 participants planned, started 2017-02-16 and due to reach its primary completion in 2028-08. Interventions recorded: Vimseltinib. Conditions listed: Advanced Malignant Neoplasm, Pigmented Villonodular Synovitis, Giant Cell Tumor of Tendon Sheath, Tenosynovial Giant Cell Tumor. No results are recorded here; the registry entry is the source.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Vimseltinib, Deciphera Pharmaceuticals (Ono), Tenosynovial giant cell tumour (TGCT), Small-molecule kinase inhibitors.
Shares DCC, Deciphera Pharmaceuticals (Ono).
Shares DCC, Deciphera Pharmaceuticals (Ono).
Shares Tenosynovial giant cell tumour (TGCT), Small-molecule kinase inhibitors.
Shares Deciphera Pharmaceuticals (Ono), Small-molecule kinase inhibitors.
Shares Deciphera Pharmaceuticals (Ono), Small-molecule kinase inhibitors.
Shares Tenosynovial giant cell tumour (TGCT), Small-molecule kinase inhibitors.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/